Register

Login

Vet Times logo
+
  • View all news
  • Vets news
  • Vet Nursing news
  • Business news
  • + More
    • Videos
    • Podcasts
  • View all clinical
  • Small animal
  • Livestock
  • Equine
  • Exotics
  • Vet Times jobs home
  • All Jobs
  • Your ideal job
  • Post a job
  • Career Advice
  • Students
About
Contact Us
For Advertisers
NewsClinicalJobs
Vet Times logo

Vets

All Vets newsSmall animalLivestockEquineExoticWork and well-beingOpinion

Vet Nursing

All Vet Nursing newsSmall animalLivestockEquineExoticWork and well-beingOpinion

Business

All Business newsHuman resourcesBig 6SustainabilityFinanceDigitalPractice profilesPractice developments

+ More

VideosPodcastsDigital Edition

The latest veterinary news, delivered straight to your inbox.

Choose which topics you want to hear about and how often.

Vet Times logo 2

About

The team

Advertise with us

Recruitment

Contact us

Vet Times logo 2

Vets

All Vets news

Small animal

Livestock

Equine

Exotic

Work and well-being

Opinion

Vet Nursing

All Vet Nursing news

Small animal

Livestock

Equine

Exotic

Work and well-being

Opinion

Business

All Business news

Human resources

Big 6

Sustainability

Finance

Digital

Practice profiles

Practice developments

Clinical

All Clinical content

Small animal

Livestock

Equine

Exotics

Jobs

All Jobs content

All Jobs

Your ideal job

Post a job

Career Advice

Students

More

All More content

Videos

Podcasts

Digital Edition


Terms and conditions

Complaints policy

Cookie policy

Privacy policy

fb-iconinsta-iconlinkedin-icontwitter-iconyoutube-icon

© Veterinary Business Development Ltd 2025

IPSO_regulated

7 May 2025

Boehringer welcomes new bluetongue vaccine approvals

Authorisations have been granted for UK and Ireland as the fight against the BTV-3 virus strain continues.

author_img

Chris Simpson

Job Title



Boehringer welcomes new bluetongue vaccine approvals

A major pharmaceutical firm has welcomed new regulatory approvals for use of its bluetongue vaccine in the UK and Ireland.

Boehringer Ingelheim’s Bultavo 3 is one of three that have been permitted for use under licence by Defra since last September amid the ongoing battle against the virus.

Now, two of those – Bultavo and Ceva Animal Health’s Bluevac 3 – have now been granted marketing authorisation in Great Britain, while Bultavo also has similar authorisation in Northern Ireland.

Boehringer said it had also been granted marketing authorisation for the vaccine by the Republic of Ireland’s Health Products Regulatory Authority in exceptional circumstances.

‘Vital role’

Findlay MacBean, the company’s UK and Ireland head of livestock, said: “Bultavo 3 plays a vital role in protecting the health of cattle and sheep and safeguarding livelihoods of those who care for them.

“This marketing authorisation demonstrates our dedication to supporting farmers and authorities in combating BTV-3.

“Transboundary animal diseases, such as bluetongue, foot-and-mouth disease and avian influenza, continue to pose a significant threat, underscoring the need for long-term preventive solutions to protect our livestock.”

More than 40 million Bultavo 3 doses have been distributed across Europe over the past year in the ongoing fight against the BTV-3 virus strain.

Field data

A total of 260 BTV-3 cases, plus one of the BTV-12 strain, have been confirmed in England and Wales since the present outbreak began last August.

Boehringer said field data compiled by the Friedrich-Loeffler-Institut (FLI) showed the Bultavo 3 vaccine did induce immunity against the virus in sheep and cattle.

It claimed that animals given Bultavo 3 “consistently showed evidence of a protective antibody response to BTV-3”.

Meanwhile, in a separate development, farmers in Scotland are being encouraged to discuss potential options for tackling the virus with their vets after vaccination against BTV-3 was permitted there.